The Executive Committee of Johnson & Johnson is the principal management group responsible for the operations and allocation of the resources of the Company. This Committee oversees and coordinates the activities of the Consumer, Pharmaceuticals and Medical Devices business segments. Each subsidiary within the business segments is, with some exceptions, managed by citizens of the country where it is located.
Dominic J. Caruso is Vice President, Finance and Chief Financial Officer of Johnson & Johnson. Mr. Caruso serves as a member of the Executive Committee, the Management Compensation Committee and Pension and Benefits Committee, and has responsibility for financial and investor relations activities.
Mr. Caruso joined Johnson & Johnson in October 1999 as Chief Financial Officer for Centocor, Inc., with the completion of the merger of Centocor and Johnson & Johnson. In 2001, Mr. Caruso was named Vice President of Finance for Ortho-McNeil Pharmaceutical, Inc. and a member of its management board. He was named Vice President, Group Finance for Johnson & Johnson's Medical Devices and Diagnostics Group, and a member of the Medical Devices and Diagnostics Group Operating Committee in May 2003. Mr. Caruso assumed responsibility for the Company's Group Finance organization in December 2005, the position he held until being named to his present position in January 2007.
Prior to joining Johnson & Johnson, he had been with Centocor since 1985 with responsibilities for finance, information management, investor relations, procurement and facility services. He also served as General Manager of Centocor's Diagnostic Division. Prior to joining Centocor, he had varied industry experiences with the audit and tax services firm, KPMG.
Mr. Caruso serves as a director of the Board of Trustees of The Children's Hospital of Philadelphia and the Delaware Valley Chapter of the Cystic Fibrosis Foundation.
Mr. Caruso graduated from Drexel University with a B.S. degree in business administration.
Peter M. Fasolo is the Vice President, Global Human Resources, responsible for the global talent, recruiting, diversity, compensation, benefits, employee relations and all aspects of the human resources agenda for the Company. Mr. Fasolo is a member of the Executive Committee, Management Compensation Committee, and Chairman of the Pension and Benefits Committee.
Mr. Fasolo first joined Johnson & Johnson in 2004 as Worldwide Vice President, Human Resources for Cordis Corporation. He was then named Vice President, Global Talent Management, with responsibility for executive assessment and development. Mr. Fasolo left Johnson & Johnson in 2007 to join Kohlberg Kravis Roberts & Co. (KKR) as Chief Talent Officer for the portfolio companies owned by the firm. He returned to Johnson & Johnson in September 2010 as Vice President, Global Human Resources.
Mr. Fasolo has more than 20 years of global experience in healthcare, having spent 13 years with Bristol-Myers Squibb in executive level, human resource roles in the pharmaceutical, medical devices and consumer segments. He serves on the Board of the Human Resources Policy Association in Washington, D.C., is a member of the Board of Directors for the Families and Work Institute in New York, and is a Trustee of the Robert Wood Johnson Hospital in New Jersey.
Mr. Fasolo earned a Ph.D. in Organizational Behavior from the University of Delaware, an M.A. in Industrial Psychology from Fairleigh Dickinson University and a B.A. in Psychology from Providence College.
Alex Gorsky is the Chairman of the Board of Directors and the Chief Executive Officer, and also serves as the Chairman of the Executive Committee.
Mr. Gorsky began his Johnson & Johnson career as a sales representative with Janssen Pharmaceutica Inc. in 1988. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing, and management. In 2001, Mr. Gorsky was appointed President of Janssen Pharmaceutical Inc., and in 2003, he was named Company Group Chairman of Johnson & Johnson's pharmaceuticals business in Europe, the Middle East and Africa. Mr. Gorsky left Johnson & Johnson in 2004 to join the Novartis Pharmaceuticals Corporation, where he served as head of the company's pharmaceuticals business in North America. Mr. Gorsky returned to Johnson & Johnson in 2008 as Company Group Chairman for Ethicon. In early 2009, he was appointed Worldwide Chairman of the Surgical Care Group and member of the Executive Committee. In September 2009, he was appointed Worldwide Chairman of the Medical Devices and Diagnostics Group. Mr. Gorsky became Vice Chairman of the Executive Committee in 2011, and in April 2012, he was elected as member of the Board of Directors and was named Chairman of the Executive Committee. In December 2012, he assumed his current position as Chairman of the Board of Directors.
A longtime advocate of diversity and inclusion, Mr. Gorsky was named the 2009 Mentor of the Year by the Healthcare Businesswomen's Association, an organization he has been involved with for many years. He is the Executive Sponsor of two Johnson & Johnson affinity groups, the Women's Leadership Initiative and the Veteran's Leadership Council. Mr. Gorsky also serves on the board of the Travis Manion Foundation.
Mr. Gorsky holds a Bachelor of Science degree from the U.S. Military Academy at West Point, NY, and spent six years in the U.S. Army, finishing his military career with the rank of Captain. Mr. Gorsky earned a Master of Business Administration degree from The Wharton School of the University of Pennsylvania in 1996.
Sandra E. Peterson is Group Worldwide Chairman, Johnson & Johnson, and member of the Executive Committee. She joined Johnson & Johnson in December 2012 and is responsible for the Consumer Group of Companies, Johnson & Johnson Supply Chain, and Information Technology.
Prior to joining Johnson & Johnson, Ms. Peterson had an extensive global career in healthcare, consumer goods and consulting. Most recently, she was chairman and chief executive officer of Bayer CropScience AG in Germany. At Bayer, she had previously served as president and chief executive officer of Bayer Medical Care and president of Bayer HealthCare AG's Diabetes Care Division.
Before joining Bayer in 2005, Ms. Peterson held a number of leadership roles at Medco Health Solutions (previously known as Merck-Medco). Among her responsibilities was the application of information technology to healthcare systems.
Ms. Peterson led research and development, quality and regulatory affairs, and procurement at Nabisco, Inc., and worked in strategy, finance and product development at Whirlpool Corporation. She began her career as a consultant at McKinsey & Company, Inc.
Ms. Peterson holds a B.A. in Government from Cornell University and an M.P.A. in Applied Economics from Princeton University. She is a member of the board of directors of The Dun & Bradstreet Corporation.
Paulus Stoffels is the Chief Scientific Officer, Johnson & Johnson, and Worldwide Chairman, Pharmaceuticals. As Chief Scientific Officer, he works with the R&D leaders across Johnson & Johnson to set the enterprise-wide innovation agenda. Dr. Stoffels serves as a member of the Executive Committee and the Management Committee.
Dr. Stoffels has more than 20 years of global experience in both pharmaceutical and HIV/AIDS research and development and has held many leadership positions within Johnson & Johnson.
Dr. Stoffels joined Johnson & Johnson in 2002 with the acquisition of Virco and Tibotec, where he was Chief Executive Officer of Virco and Chairman of Tibotec. In 2005, he was appointed Company Group Chairman, Global Virology where he led the development of PREZISTA® and INTELENCE®, leading products for the treatment of HIV.
In 2006, he assumed the role of Company Group Chairman, Pharmaceuticals, with responsibility for worldwide research and development for the CNS and Internal Medicine Franchises. Dr. Stoffels was appointed Global Head, Research & Development, Pharmaceuticals, in 2009 and in 2011 became Worldwide Chairman, Pharmaceuticals Group, with responsibility for research and development, business development and global strategy and innovation. In this role, he leads global teams across Janssen to discover and develop innovative medicines and vaccines for unmet medical needs worldwide and to leverage the power of science for global health.
In October 2012, Dr. Stoffels was appointed Chief Scientific Officer, Johnson & Johnson. He chairs the company’s Worldwide Research & Development Council, and provides oversight to Johnson & Johnson Development Corporation, the Johnson & Johnson innovations centers, and for product safety for all products of the Johnson & Johnson Family of Companies worldwide.
Dr. Stoffels began his career as a physician in Africa, as part of the Janssen Research Foundation (JRF) under the mentorship of Dr. Paul Janssen, focusing on HIV and tropical diseases research. He studied Medicine at the University of Diepenbeek and the University of Antwerp in Belgium and Infectious Diseases and Tropical Medicine at the Institute of Tropical Medicine in Antwerp, Belgium.
Throughout his career, Dr. Stoffels has had a passion saving lives and improving quality of life and for using the power of science to solve health care challenges in the developing world. He was instrumental in building the relationship between UNAIDS/WHO and the pharmaceutical industry on provision of HIV drugs in Africa, and has a continued interest in exploring new and collaborative solutions to address serious unmet healthcare needs in the developing world. Dr. Stoffels also represents Johnson & Johnson in discussions on global health topics at international forums such as the annual World Economic Forum in Davos, Switzerland and the Pacific Health Summit.
Michael H. Ullmann is Vice President, General Counsel of Johnson & Johnson and a member of the Executive Committee. He has responsibility for the Law Department, Global Security and Aviation.
Mr. Ullmann joined Johnson & Johnson as a mergers and acquisitions attorney in 1989. He also served on the Management Boards of Johnson & Johnson Consumer Products Company, Inc., Janssen Pharmaceuticals, Inc. (U.S.), McNeil Pharmaceuticals and Johnson & Johnson Sales and Logistic Company, LLC. Mr. Ullmann served as Corporate Secretary from 1999 to 2006. During that time, he also held various management positions in the Law Department. In 2002, Mr. Ullmann was appointed as a member of the Law Department Operating Committee and Associate General Counsel. In 2006, Mr. Ullmann was appointed General Counsel of the Medical Devices and Diagnostics Group. He assumed his current responsibilities in January 2012.
Prior to joining Johnson & Johnson, Mr. Ullmann practiced law in New York City.
He graduated magna cum laude from Cornell University, College of Arts & Sciences, and earned his law degree from Columbia University School of Law.
For more information: